Economic evaluation of health promotion for older people-methodological problems and challenges

BMC Health Services Research

Volumn 16, Issue , 2016, Pages

  Huter, Kai ^a   Kocot, Ewa ^b   Kissimova Skarbek, Katarzyna ^b   Dubas Jakóbczyk, Katarzyna ^b   Rothgang, Heinz ^a  

^a UNIVERSITY OF BREMEN   (Germany)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Age based rationing; Cost effectiveness; Costs; Economic evaluation; Health promotion; Older people; QALY

Indexed keywords

CAREGIVER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH PROMOTION; HUMAN; QUALITY ADJUSTED LIFE YEAR; AGED; COST BENEFIT ANALYSIS; ECONOMICS; ELDERLY CARE; EUROPE; HEALTH CARE PLANNING; PRODUCTIVITY;

AGED; CAREGIVERS; COST-BENEFIT ANALYSIS; DECISION MAKING; EFFICIENCY; EUROPE; HEALTH PROMOTION; HEALTH RESOURCES; HEALTH SERVICES FOR THE AGED; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84986308342     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-016-1519-y     Document Type: Review

References (69)

1. Westerhout E. Population ageing and health care expenditure growth. In: International Handbook on Ageing and Public Policy. Cheltenham & Northampton: Edward Elgar; 2014. p. 178-90.
2. Mathar T, Jansen YJFM. Health Promotion and Prevention Programmes in Practice: How Patients' Health Practices Are Rationalised, Reconceptualised and Reorganised. Bielefeld: transcript; 2010.
3. Drummond MF, Sculpher MJ, Torrance GW, O'Brian BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford/New York: Oxford University Press; 2005.
4. Edlin R. Assessing the cost-effectiveness of therapies for older people. In: Harper S, Hamblin K, editors. International Handbook on Ageing and Public Policy. Cheltenham & Northampton: Edward Elgar; 2014. p. 167-77.
5. McDaid D, Sassi F, Merkur S. Supporting effective and efficient policies: the role of economic analysis. In: McDaid D, Sassi F, Merkur S, editors. Promoting Health, Preventing Disease. The economic case, European Observatory on Health Systems and Policies Series. New York: Open University Press; 2015. p. 19-31.
6. Palmer S, Raftery J. Opportunity cost. BMJ. 1999;318:1551-2.
7. World Health Organization. Ottawa Charter for Health Promotion. World Health Organization: Geneva; 1986.
8. Cohen D. Health promotion and cost-effectiveness. Health Promot Int. 1994;9:281-7.
9. Edwards RT, Charles JM, Lloyd-Williams H. Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues. BMC Public Health. 2013;13:1001.
10. Hale J. What contribution can health economics make to health promotion? Health Promot Int. 2000;15:341-8.
11. Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, Rice N, Sculpher M, Sowden A. Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations. Health Policy. 2009;93:85-92.
12. Nutbeam D. Evaluating health promotion - progress, problems and solutions. Health Promot Int. 1998;13:27-44.
13. Richardson J. Economic evaluation of health promotion: friend or foe? Aust N Z J Public Health. 1998;22:247-53.
14. de Salazar L, Jackson S, Shiell A, Rice M. Guide to Economic Evaluation in Health Promotion. Washington, D.C: Pan American Health Organization; 2007.
15. University of York, NHS Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: CRD, University of York; 2009.
16. Rychetnik L, Frommer M. A Schema for Evaluating Evidence on Public Health Interventions. Melbourne: National Public Health Partnership; 2002.
17. Centers for Disease Control and Prevention. Introduction to Program Evaluation for Public Health Programs: A Self-Study Guide. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. Office of the Director, Office of Strategy and Innovation, Atlanta; 2011.
18. Cairns J. Discounting in economic evaluation. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001. p. 236-55.
19. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2011;20:2-15.
20. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford Univ Press; 1996.
21. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ. 2007;16:307-17.
22. Lazaro A, Barberan R, Rubio E. The economic evaluation of health programmes: why discount health consequences more than monetary consequences? Appl Econ. 2002;34:339-50.
23. Meltzer DO, Smith PC. Theoretical issues relevant to the economic evaluation of health technologies. In: Pauly MV, McGuire TG, Barros PLP, (eds). Handbook of Health Economics Vol. 2. Amsterdam [etc.]: North Holland; 2012. pp. 433-469.
24. Mogyorosy Z, Smith P. The Main Methodological Issues in Costing Health Care Services: A Literature Review, CHE Research Paper 7. York: Centre for Health Economics; 2005.
25. Rothgang H, Salomon T. Die ökonomische Evaluation von Gesundheitsförderung und Prävention. In: Kolip P, Müller V, editors. Qualität von Gesundheitsförderung und Prävention. Bern: Verlag Hans Huber; 2009. p. 345-62.
26. Goodrich K, Kaambwa B, Al-Janabi H. The inclusion of informal care in applied economic evaluation: a review. Value Health. 2012;15:975-81.
27. Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluations. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001. p. 68-93.
28. Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ. 1996;5:13-23.
29. van den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care. Eur J Health Econ. 2004;5:36-45.
30. van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GAM, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62:835-45.
31. van den Berg B, Ferrer-i-Carbonell A. Monetary valuation of informal care: the well-being valuation method. Health Econ. 2007;16:1227-44.
32. Koopmanschap MA, van Exel JNA, van den Berg B, Brouwer WBF. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics. 2008;26:269-80.
33. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253-8.
34. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs measurement through quality of life? a response to the recommendation of the Washington panel. Health Econ. 1997;6:253-9.
35. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 1997;6:511-4.
36. Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001. p. 94-112.
37. Koopmanschap M, Burdorf A, Jacob K, Jan Meerding W, Brouwer W, Severens H. Measuring productivity changes in economic evaluation: setting the research agenda. Pharmacoeconomics. 2005;23:47-54.
38. Claxton K, Walker S, Palmer S, Sculpher M. Appropriate Perspectives for Health Care Decisions (CHE Research Paper No. 54). New York: Centre for Health Economics; 2010.
39. Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics. 2013;31:537-49.
40. Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32:335-44.
41. Rappange DR, van Baal PHM, van Exel NJA, Feenstra TL, Rutten FFH, Brouwer WBF. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics. 2008;26:815-30.
42. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16:33-64.
43. van Baal PHM, Feenstra TL, Hoogenveen RT, Ardine de Wit G, Brouwer WBF. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a "perfect" cost-utility ratio. Health Econ. 2007;16:421-33.
44. Felder S. Lebenserwartung, medizinischer Fortschritt und Gesundheitsausgaben: Theorie und Empirie. Perspekt Wirtsch Suppl. 2006;7:49-73.
45. Breyer F, Felder S. Life expectancy and health care expenditures: a new calculation for Germany using the costs of dying. Health Policy. 2006;75:178-86.
46. Gandjour A, Lauterbach KW. Does prevention save costs? J Health Econ. 2005;24:715-24.
47. Gandjour A. Aging diseases - do they prevent preventive health care from saving costs? Health Econ. 2009;18:355-62.
48. van Baal PHM, Feenstra TL, Polder JJ, Hoogenveen RT, Brouwer WBF. Economic evaluation and the postponement of health care costs. Health Econ. 2011;20:432-45.
49. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24:751-73.
50. Cookson R, Drummond M, Weatherly H. Explicit incorporation of equity considerations into economic evaluation of public health interventions. Health Econ Policy Law. 2009;4:231.
51. Round R, Marshall B, Horton K. Planning for Effective Health Promotion Evaluation. Melbourne: Victorian Government Deptartment of Human Services; 2005.
52. Rothgang H, Greß S, Niebuhr D, Wasem J. Der Oregon Health Plan: ein Beispiel für "rationale Rationierung"? Sozialer Fortschr Ger Rev Soc Policy. 2004;53:206-19.
53. McGregor M. Cost-utility analysis: Use QALYs only with great caution. Can Med Assoc J. 2003;168:433-4.
54. Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health. 2009;12:10-5.
55. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5-21.
56. Edlin R, Round J, McCabe C, Sculpher M, Claxton K, Cookson R. Cost-Effectiveness Analysis and Ageism: A Review of the Theoretical Literature. A Report for the Department of Health. Leeds: University of Leeds; 2008.
57. Salomon T, Rothgang H, AGil-Projekt. Gesundheitsökonomische Evaluation bei Leistungen für Senioren: Führen diese zu einer Benachteiligung gesundheitsfördernder und präventiver Maßnahmen? Prävent Gesundheitsförderung. 2011;6:138-44.
58. Hickey DA, Barker M, McGee H, O'Boyle C. Measuring health-related quality of life in older patient populations. Pharmacoeconomics. 2005;23:971-93.
59. Cookson R, Culyer AJ. Measuring overall population health: the use and abuse of QALYs. In: Evidence-based Public Health: Effectiveness and Efficiency. Edited by Killoran A, Kelly MP, editors. Oxford: Oxford University Press; 2010:148-168.
60. Weinstein MC. A QALY Is a QALY Is a QALY - Or Is It? J Health Econ. 1988;7:289-90.
61. Makai P, Brouwer WBF, Koopmanschap MA, Stolk EA, Nieboer AP. Quality of life instruments for economic evaluations in health and social care for older people: a systematic review. Soc Sci Med. 2014;102:83-93.
62. Coast J, Flynn TN, Natarajan L, Sproston K, Lewis J, Louviere JJ, Peters TJ. Valuing the ICECAP capability index for older people. Soc Sci Med. 2008;67:874-82.
63. Grewal I, Lewis J, Flynn T, Brown J, Bond J, Coast J. Developing attributes for a generic quality of life measure for older people: Preferences or capabilities? Soc Sci Med. 2006;62:1891-901.
64. Couzner L, Ratcliffe J, Lester L, Flynn T, Crotty M. Measuring and valuing quality of life for public health research: application of the ICECAP-O capability index in the Australian general population. Int J Public Health. 2013;58:367-76.
65. Davis JC, Liu-Ambrose T, Richardson CG, Bryan S. A comparison of the ICECAP-O with EQ-5D in a falls prevention clinical setting: are they complements or substitutes? Qual Life Res. 2013;22:969-77.
66. Makai P, Looman W, Adang E, Melis R, Stolk E, Fabbricotti I. Cost-effectiveness of integrated care in frail elderly using the ICECAP-O and EQ-5D: does choice of instrument matter? Eur J Health Econ. 2014;16:437-50.
67. Makai P, Koopmanschap MA, Brouwer WB, Nieboer AA. A validation of the ICECAP-O in a population of post-hospitalized older people in the Netherlands. Health Qual Life Outcomes. 2013;11:57.
68. Makai P, Beckebans F, van Exel J, Brouwer WBF. Quality of Life of Nursing Home Residents with Dementia: Validation of the German Version of the ICECAP-O. PLoS ONE. 2014;9:e92016. doi:10.1371/journal.pone.0092016.
69. NICE (National Institute for Health and Care Excellence). Developing NICE Guidelines: The Manual. Process and methods guides; 2014.